EPISODE · Dec 17, 2025 · 8 MIN
Update on Reproxalap PDUFA Timing
from Eyewire News: The Podcast · host Eyewire News
Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans. Learn more about your ad choices. Visit megaphone.fm/adchoices
NOW PLAYING
Update on Reproxalap PDUFA Timing
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m